Table 2.
Results of CMP.
| Prosthesis | Author | Year | A | B | C | D | E | F | G | H |
|---|---|---|---|---|---|---|---|---|---|---|
| Evolution-K® | 2015 | 16 (15-18) | 54.5 (34-64) | 50 | 5 | 79 | 4 | 4 | 92 | |
| Adaptiva® | 2015 | 13 (13-15) | 57 (42-66) | 59 | 5 | 88 | 1 | 1 | 99 | |
| CAD-CAM® | Muirhead-Allwood et al. | 2010 | 13 (10-17) | 46 (25-62) | 112 | 6 | 90 | 0 | 0 | 100 |
| Sewell et al. | 2011 | 10 (4-18) | 38 (18-61) | 43 | 3 | 80 | 2 | 1 | 93 | |
| Benum et Aamodt | 2010 | 10 | 48 (20-65) | 83 | 0 | - | 2 | 0 | 98 | |
| Al-Khateeb et al. | 2014 | 10 (5-15) | 33 (23-55) | 17 | 0 | 80 | 0 | 0 | 100 | |
| Symbios® | Flecher et al. | 2010 | 10 (5-16) | 40 (18-50) | 232 | 0 | 97 | 6 | 2 | 97 |
| Pakos et al. | 2015 | 10 (8-12) | 48 (41-55) | 86 | 0 | - | 4 | 2 | 98 | |
| CT3D-A® | Akbar et al. | 2009 | 14 (10-16) | 35 (22-40) | 72 | 0 | 87 | 0 | 0 | 100 |
A: Mean follow-up period [years]. B: Median age of the collective [years]. C: Collective size [n]. D: Lost to follow up [n]. E: HHS-result [points]. F: Number of revisions [n]. G: Number of revisions due to aseptic loosening [n]. H: Survival rates [%].